Currently, the primary clinical treatments include inhibitors targeting different enzymes in the kynurenine pathway, such as IDO1 inhibitors, TDO inhibitors, and KMO inhibitors, which have shown efficacy in cancer, immune diseases, neurological diseases, and neurodegenerative diseases (Table 2). The gene discussed is KMO; the disease is cancer.